You are here


Endogenous overstimulation of the so-called detrimental arm of the Renin-Angiotensin System (RAS) plays an important role in the initiation and progression of cardiovascular, renal and other diseases. In contrast, stimulation of so-called protective RAS, especially AT2- or Mas receptors, may counterbalance the detrimental effects and offers a novel strategy for treatment of diseases with high unmet medical need. Lanthio Pharma has discovered lanthionine-constrained agonists of the protective RAS receptors, subject of three development programs.


Apelins are the endogenous peptide ligands for the APJ receptor. Lanthio Pharma has discovered highly active and stable lanthi-apelins that differentially stimulate APJ-receptor–coupled intracellular pathways (biased agonism).


Natural galanin acts via three different receptor subtypes, GalR1, GalR2 and GalR3. Lanthio Pharma has discovered lanthi-galanins with enhanced subtype receptor specificities.